Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 44 Breast Neoplasms 42 Lung Neoplasms 27 Carcinoma, Non-Small-Cell Lung 21 Colorectal Neoplasms 19 Uterine Cervical Neoplasms 13 Prostatic Neoplasms 13 Ovarian Neoplasms 11 Head and Neck Neoplasms 11 Carcinoma, Hepatocellular 11 Pancreatic Neoplasms 10 Melanoma 10 Brain Neoplasms 9 Sarcoma 7 Neoplastic Cells, Circulating 7 Myelodysplastic Syndromes 7 Glioma 7 Esophageal Neoplasms 7 Endometrial Neoplasms 7 Multiple Myeloma 6 Gastrointestinal Neoplasms 6 Disease 6 Carcinoma, Renal Cell 6 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 5 Leukemia, Myeloid, Acute 5 Colonic Neoplasms 5 Uveal Melanoma 4 Skin Neoplasms 4 Neoplasm, Residual 4

Interventions

Trastuzumab 14 pertuzumab 10 Docetaxel 7 tucatinib 4 pyrotinib 4 Paclitaxel 4 Capecitabine 4 Carboplatin 2 Ado-Trastuzumab Emtansine 2 trastuzumab deruxtecan 1 pegfilgrastim 1 neratinib 1 exemestane 1 dalpiciclib 1 atezolizumab 1 Neoadjuvant Therapy 1 Leuprolide 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Goserelin 1 Genetic Testing 1 Fulvestrant 1 Fluorodeoxyglucose F18 1 Blood Specimen Collection 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Blood Specimen Collection × 1 year × Clear all

NCT04638725 2026-06-04

SIGHER

Centre Paul Strauss

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡